Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Seqens Innovative & Generic Pharmaceuticals (I&GP) North America | Contract Pharma

What are you searching for?

Sign in

Search by

Seqens Innovative & Generic Pharmaceuticals (I&GP) North America

Company Headquarters

9 Opportunity Way , Newburyport, MA, 01950, US

Driving Directions Phone: View Phone Fax: View Fax
View website

Request more information from Seqens Innovative & Generic Pharmaceuticals (I&GP) North America

Request more information from Seqens Innovative & Generic Pharmaceuticals (I&GP) North America

Categories from Seqens Innovative & Generic Pharmaceuticals (I&GP) North America

Analytical Laboratory Services
cGMP Synthesis
CMC (Chemistry, Manfacturing & Controls)
Contract Development and Manufacturing Organization (CDMO)
Manufacturing, API
Manufacturing, Custom
Manufacturing, Generics
Micronization
Organic Synthesis
Process Development/Scale-Up Services
Process R&D
Process Validation Studies
Quality Control Testing
R&D Services
Stability, ICH

Related Content

Collaborations & Alliances

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026. 

By: Rachel Klemovitch

Promotions & Moves

Seqens Names Pascal Villemagne as CEO

Villemagne previously served as CEO of Carbogen Amcis.

By: Charlie Sternberg

Breaking News

Biophytis Partners with Seqens to Produce Sarconeos Active Compound

SEQENS will produce the active ingredient in Sarconeos (BIO101) in France at its Villeneuve La Garenne plant.

Online Exclusives

CEO Spotlight: Pierre Luzeau on Seqens U.S. R&D Lab Investment

Luzeau discusses expansion into U.S. markets, outsourcing trends, and the company’s plan for continued growth in the CDMO space.

Breaking News

Seqens Opens Flagship R&D Center in Greater Boston

Invests $5 million in a state-of-the-art, 15,000 sq.-ft. R&D center in Devens, MA.

Breaking News

SEQENS Invests in U.S. R&D Lab Expansion

Increases R&D capability and productivity in the U.S. and builds on merger with CDMO Wavelength Pharmaceuticals.

Collaborations & Alliances

Virpax Inks MMS019 Manufacturing and Supply Agreement

CDMO Seqens to provide clinical and commercial supply of MMS019.

Promotions & Moves

Seqens Taps Managing Director for North America

Jean-Noel David was previously a VP at Patheon Biologics.

Breaking News

Seqens Opens New HPAPI Unit

Will produce highly active ingredients at its Villeneuve-La-Garenne site.

Breaking News

Seqens CDMO Enhances Flow Chemistry Capabilities

Seqens’ Lab to add GMP pilot plant by end of 2020

Breaking News

Seqens Unveils Innovation and Development CoE

SEQENS'Lab is a development accelerator located just out of Paris

Breaking News

PCI Synthesis to Become SEQENs

The name change comes six months after PCI Synthesis was acquired by Novacap

Breaking News

Novacap Acquires PCI Synthesis

Expands pharma offering in the U.S.

Videos

Predictions for the Generic Drug Sector in 2018

PCI Synthesis shares expected trends in the industry within the next year

Promotions & Moves

PCI Synthesis Hires New Business Development Manager

The new addition has over twenty years of industry experience, and will be based out of California